CNXU

Conexeu Sciences Inc

3.06

Oct 16 • 3:59 PM ET -0.89 (-22.53%)

3.28

Aftermarket • 7:30 PM ET +0.22 (7.03%)

Healthcare Biotechnology USA Micro NASD

Today, 8:31 PMDiscounted $5M private placement with warrants sinks CNXU 23% in regular hours

Peers: CGEM GERN RIGL ARVN BBOT CTMX JANX KURA XNCR IDYA

| Held by: VXF VTI

Scroll to Statements

Index	-
Market Cap	86.32M
Enterprise Value	84.18M
Income	-13.63M
Sales	0.00M
Book/sh	0.21
Cash/sh	0.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	May 21, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	14.33
P/C	39.06
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.31
Current Ratio	5.31
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.54
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-950.49% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-1549.12%
Sales Q/Q	-
Earnings	Jul 01
EPS/Sales Surpr.	0.00% -

Insider Own	60.17%
Insider Trans	1.02%
Inst Own	7.59%
Inst Trans	85.94%
ROA	-
ROE	-
ROIC	-231.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.49%
SMA50	-44.50%
SMA200	-63.62%
Trades

Shs Outstand	27.40M
Shs Float	11.24M
Short Float	1.87%
Short Ratio	0.90
Short Interest	0.21M
52W High	18.79 -83.72%
52W Low	3.05 0.32%
Volatility	22.10% 13.33%
ATR (14)	0.59
RSI (14)	36.86
Beta	-
Rel Volume	2.84
Avg Volume	234.07K
Volume	664,467

Perf Week	-21.34%
Perf Month	-42.26%
Perf Quarter	-65.54%
Perf Half Y	-
Perf YTD	-77.33%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	20.00
Prev Close	3.95
Price	3.06
Change %	-22.53%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-26	Initiated	H.C. Wainwright	Buy	$20

Oct-15-26 04:30PM	Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors (GlobeNewswire) +8.37% -22.53%
Oct-06-26 08:30AM	Conexeu Sciences Advances Ten Minute Tissue Toward Planned FDA 510(k) Submission (GlobeNewswire) +17.31%
Sep-01-26 11:37AM	A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture (PR Newswire) -18.19%
08:30AM	Conexeu Sciences Sets September and October 2026 Conference Schedule (GlobeNewswire)
Aug-18-26 08:30AM	Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration (GlobeNewswire)
08:30AM	Loading…
Aug-11-26 08:30AM	Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration (GlobeNewswire)
Aug-03-26 10:55AM	Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (Ipo Edge) -6.62%
Jul-15-26 11:01AM	The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. (PR Newswire) +17.68%
Jul-14-26 08:30AM	The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It (GlobeNewswire) -8.12%
Jul-09-26 08:16AM	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
Jul-07-26 09:45AM	A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It (PR Newswire) -12.13%
09:00AM	A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill (GlobeNewswire)
Jun-25-26 08:30AM	Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform (GlobeNewswire)
Jun-16-26 08:15AM	Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower (PR Newswire) +27.49%
Jun-15-26 08:30AM	Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing (GlobeNewswire) -13.02%
08:30AM	Loading…
Jun-08-26 08:30AM	Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU Wound Care Program (GlobeNewswire)
Jun-03-26 08:30AM	Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026 (GlobeNewswire)
Jun-02-26 09:00AM	The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts (PR Newswire) +19.26%
May-27-26 10:36AM	UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T. Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine (GlobeNewswire)
May-22-26 10:31AM	Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It (PR Newswire) +10.18%
May-21-26 12:02PM	Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol 'CNXU' (Newsfile)

Conexeu Sciences, Inc. engages in the development of regenerative biomaterials needed in wound care, dentistry, and aesthetics. The company was founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell on November 2, 2022 and is headquartered in Reno, NV.

PresidentMr. Miles D. Harrison

FounderMr. David R. Bogart

Ph.D.Dr. Claudia Chavez-Munoz M.D.

CFOMr. Stephen D. Inouye

Chief Medical OfficerDr. Brian K. Pilcher Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bogart David Robert	Chief Commercial Officer	Sep 25 '26	Option Exercise	0.00	750,000	750	1,812,500	Sep 28 05:38 PM
Sharpe Jeffrey Nathan	Director	Sep 14 '26	Option Exercise	0.00	500,000	500	1,500,000	Sep 15 04:30 PM
Purcell Lynn Sebastian	Director	Jun 18 '26	Buy	0.80	202,500	162,000	2,734,240	Jun 23 08:15 PM
Wright Michael G.	10% Owner	Jun 18 '26	Option Exercise	0.00	250,000	250	2,148,048	Jun 22 01:25 PM
Wright Michael G.	10% Owner	May 26 '26	Option Exercise	0.00	400,000	400	1,898,048	May 28 11:39 AM
Sharpe Jeffrey Nathan	Director	May 22 '26	Option Exercise	0.00	500,000	500	1,000,000	May 26 06:16 AM

CNXU

Conexeu Sciences Inc

Upgrade your Finviz experience